News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Cambrex Corporation (CBM) And Epoch Biosciences, Inc. (EBIO) Announce Licensing Deal For Rapid Microbial Detection

10/19/2005 5:11:50 PM

EAST RUTHERFORD, N.J., and BOTHELL, Wash., Oct. 14 /PRNewswire-FirstCall/ -- Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation and Epoch Biosciences, Inc. , a provider of proprietary products that accelerate genomic analysis, are pleased to announce that they have entered into a worldwide license whereby Cambrex Bioproducts will incorporate Epoch's MGB Eclipse(TM) Probe System technology into its rapid microbial detection testing products and services.

Under the license and supply agreement, Cambrex receives a non-exclusive license to MGB Eclipse technologies and an exclusive license to probe sequences developed for specific patented primer sequences supplied by Cambrex. Epoch will receive an upfront payment for technology access, product sales from shipments of MGB Eclipse probes and primers to Cambrex, royalties on Cambrex's sales of testing systems and services to end-users, and contract development revenue for specific product optimization. Other financial terms were not disclosed.

William G. Gerber, M.D., Chief Executive Officer of Epoch, said, "This agreement increases the reach of our technology and products into the global microbiology testing market. Epoch's analytical tools are broadly useful in the detection of microorganisms in a variety of settings, support quality assurance professionals in achieving corporate and regulatory standards, and help protect consumers from contamination due to equipment failure, manufacturing process error, deliberate sabotage or bioterrorism. This accord with Cambrex, our second licensing deal in industrial quality control testing, further validates our technology in this important sector. It strengthens our position in industrial genomics, our third major market along with molecular diagnostics and research applications. We expect this collaboration to generate revenue for Epoch beginning in the fourth quarter of 2004."

"This licensing agreement with Epoch demonstrates our commitment to provide customers with rapid, accurate and cost-effective microbial detection solutions," commented Dave Eansor, President, Cambrex Bioproducts. "Epoch's technology is complementary to our own and will enable us to build upon our endotoxin detection and mycoplasma screening testing platforms. We expect to swiftly integrate the technology into new products for rapid microbial detection, a necessity for cell therapy and biologics customers who are looking for a rapid release test and to meet the aims and objectives of the FDA's Process Analytical Technology (PAT) initiative."

MGB Eclipse Probe Systems

MGB Eclipse Probe Systems are probe and primer sets used for a variety of genetic analysis applications, such as gene expression profiling, SNP analysis, and pathogen detection. The systems are compatible with the existing installed base of real-time PCR instruments and reagent systems that have been widely adopted around the world and are considered the gold standard in genetic sequence detection.

About Epoch Biosciences

Epoch Biosciences, Inc. develops and sells proprietary products with commercial applications in the genomics and molecular diagnostics fields. Epoch's technology has numerous applications including the detection of inherited diseases, single nucleotide polymorphisms (SNPs) to identify individuals at risk for disease or adverse drug reactions, and gene expression measurement. The company's chemical reagents enhance the performance of genetic analysis procedures, and are compatible with the majority of DNA analysis systems currently employed or under development for research and diagnostic use. The company has an established presence in the research market through licenses to leading genomics companies, global distribution agreements and direct sales to end-users. Epoch also participates in the industrial genomic sector and has entered the diagnostics market. Epoch recently announced the signing of a definitive agreement to merge with Nanogen, Inc. , a San Diego-based developer of advanced in vitro diagnostic products. Information about Epoch is available at

About Cambrex Bio Science Walkersville

Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex Corporation , is a leading provider of normal human cells systems; research and therapeutic media; cell therapy services; endotoxin detection products, services and WinKQCL(R) software; electrophoresis and chromatography products; products and services for rapid testing, including custom assay development; regulatory services; and therapeutic commercialization solutions.

About Cambrex Corporation

Cambrex is a global, diversified life science company dedicated to providing high quality products and services to accelerate the discovery, development, and manufacturing processes of human therapeutics. The Company employs approximately 1900 worldwide. For more information, please visit our website at

Epoch Biosciences Safe Harbor Statement

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties, including but not limited to the possibility that the products utilizing Epoch Biosciences' technologies may not be commercially successful or that third parties assert proprietary rights that preclude Epoch or its distributors from marketing Epoch's products and technologies. These factors and others may cause actual results to differ materially from the anticipated results. Additional information about potential risk factors that could affect Epoch's business and financial results is included in Epoch's Annual Report on Form 10-K for the year ended December 31, 2003 and in other reports filed from time to time with the Securities and Exchange Commission. These forward-looking statements speak only as to the date of this release and Epoch undertakes no obligation to update or revise the forward-looking statements, whether as a result of new information, future events, or otherwise.

Cambrex Forward Looking Statements

This news release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under The Exchange Act, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities. These statements may be identified by words such as "expects", "anticipates", "intends", "estimates", "believes" or similar expressions in connection with any discussion of future financial and operating performance.

The forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and/or regulations (particularly environmental issues), tax rate, technology, manufacturing and legal issues, unfavorable results shipments, changes in foreign exchange rates, performance of minority investments, un-collectable receivables, loss on disposition of assets, cancellation or delays in renewal of contracts, and lack of suitable raw materials or packaging materials. For further details and a discussion of these and other risks and uncertainties, investors are cautioned to review the Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement section therein, and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Eclipse is a trademark of Epoch Biosciences, Inc. WinKQCL(R) is a registered trademark of Cambrex Corporation.

Cambrex Corporation; Epoch Biosciences, Inc.

CONTACT: Bert W. Hogue, Chief Financial Officer of Epoch Biosciences,Inc., +1-425-482-5555; or Anne-Marie Hess, Director, Investor Relations ofCambrex Corporation, +1-201-804-3062, or; orInvestor Relations, Jonathan Fassberg or Brian Korb, both of The Trout Group,+1-212-477-9007, for Cambrex Corporation and Epoch Biosciences, Inc.

Read at

comments powered by Disqus